TB R&D Weekly Update: Drugs Targeting MMP-1 May Reduce Lung Pathology Caused by TB

Paul Elkington, Takayuki Shiomi, Ronan Breen, Robert K. Nuttall, Cesar Augusto Ugarte-Gil, Naomi F. Walker, Luísa Saraiva, Bernadette Pedersen, Francesco Mauri, Marc Lipman, Dylan R. Edwards, Brian D. Robertson, Jeanine D’Armiento and Jon S. Friedland. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest. 2011 Apr 25. [Epub ahead of print]

On March 1, 2011, we reviewed an article by Elkington, et al., that sought to redefine TB immunopathology by taking in account lung destruction by proteases. This week, Elkington, et al., presents significant data to support the premise that M. tuberculosis infection drives proteolytic destruction of the lung matrix contributing to lung damage caused by TB and to the morbidity and mortality of TB.

The authors focused on a family of proteases called MMPs which are zinc-dependent and can degrade all components of the extracellular matrix of the lung. MMPs are inhibited by TIMPs (tissue inhibitor of metalloproteinases). The series of experiments utilized clinical samples, primary human monocytes, and transgenic mice. Key points from the article include:

  • After analyzing clinical samples for concentrations of all MMPs, TIMPs, and related cell surface proteins, MMP-1 emerged as the principal secreted collagenase upregulated in TB. MMP-3 was also upregulated but to a lesser extent. Control samples were from patients with respiratory systems but did not have a final diagnosis of TB.
  • Analyzing samples from TB/HIV co-infected patients, MMP-1 still had increased concentrations. In HIV-negative TB patients, those with more extensive lung disease had higher MMP-1 concentrations.
  • Experiments with human monocytes and UV killed M. tb. demonstrated that MMP-1 could be upregulated in the absence of live mycobacteria.
  • Ro32-3555, a drug partially developed by Roche and used in Phase III clinical trials for arthritis, was shown to completely inhibit MMP-1 activity in M. tb.-infected primary human macrophages.
  • Mice do not have the tissue destruction seen in human disease. Wild type mice had intact alveolar walls when infected with M. tb. ,whereas, mice expressing human MMP-1 showed destroyed alveolar walls at the sites of infection.

Additional TB R&D News:

TB study points to drugs to halt lung destruction

Eliminating TB, curbing AIDS orphans with ART scale-up, and more…

Biomagnetics Receives Delivery of World’s First Integrated Optical Biosensor for Disease Diagnosis from Los Alamos National Laboratory

Supramolecular assemblies of rifampicin and cationic bilayers: preparation, characterization and micobactericidal activity

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...